Trials / Unknown
UnknownNCT02898376
Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer
Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- Sponsor
- Institut de Cancérologie de Lorraine · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the dermatological life quality six months after spa cares in patients with severe late toxicity involving the skin and / or soft tissues after postoperative radiotherapy for breast cancer. Half of the patients will be treated with a combination of pentoxifylline (PTX) and alpha-tocopherol (Vit E) when Half of the patients will receive skin-oriented spa cares in addition.
Detailed description
The combination of PTX and vit E appears as the standard treatment of radiation induced fibrosis. Synergism between PTX and Vit E is likely, as treatment with each drug alone is ineffective. This combination was also positively evaluated in the treatment of osteoradionecrosis, radiation-induced pelvic neuropathies, pneumoniae as well as bowel pathologies. Spa cares are part of the standard treatment of burn scars. Two spa treatments per year enable the mitigation or disappearance (after several treatments) of pruritus, dysesthesia, local inflammation, hypertrophy and sclerosis. They promote the healing of chronic superficial erosions. The spa treatment combines baths, sprays and especially filiform showers with thermal water jets under high pressure for a few minutes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | skin-oriented spa care | standardized procedure : 72 care sessions over 18 days of treatment +/- Additional care according to the specificity of each spa |
| DRUG | Pentoxifylline | 400 mg bid during at least 6 months |
| DRUG | Tocopherol acetate | 500 mg bid during at least 6 months |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2020-07-01
- Completion
- 2021-12-01
- First posted
- 2016-09-13
- Last updated
- 2018-08-08
Locations
21 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02898376. Inclusion in this directory is not an endorsement.